Results 111 to 120 of about 93,278 (263)

Cardiometabolic Biomarkers for Disease Severity Prediction in Metabolic Dysfunction‐Associated Steatotic Liver Disease

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The impacts of cardiometabolic risk factors (CMRFs) and the biomarkers on disease severity in metabolic dysfunction‐associated steatotic liver disease (MASLD) remain elusive. Accordingly, a multicenter study by recruiting MASLD patients from a nationwide registry database was conducted with a total of 2882 MASLD patients (54.1% males, mean age 
Jee‐Fu Huang, Chi‐Yi Chen, Ming‐Jong Bair, Tzu‐Chun Lin, Ming‐Lun Yeh, Pei‐Chien Tsai, Yu‐Ju Wei, Chih‐Wen Wang, Po‐Chen Liang, Ming‐Yen Hsieh, Mei‐Hsuan Lee, Chia‐Yen Dai, Chung‐Feng Huang, Ming‐Lung Yu, Wan‐Long Chuang   +14 more
wiley   +1 more source

Factors associated with angiotensin II stimulating vs. inhibiting antihypertensive drug use in older adults. [PDF]

BMC Geriatr
Shrestha N, Cheng TD, Worley M, Lin C, Young H, Russo M, Wei YJ.   +6 more
europepmc   +1 more source

Prioritizing Modifiable Risk Factors for Cardiovascular Diseases in Adults With Hypertension: A Prospective Cohort Study

Med Research, EarlyView.
This study examined the relative contributions of modifiable risk factors to cardiovascular diseases in adults with hypertension. More favorable risk factor profiles were consistently associated with lower risks across all outcomes. Beyond blood pressure, nicotine exposure showed comparatively larger population attributable fractions.
Shengtao Wei, Dashan Zheng, Lan Chen, Zitong Zhuang, Zihan Lin, Junguo Zhang, Peng Hu, Zijun Yang, Zhen‐He Huang, Bing Zhang, Hualiang Lin   +10 more
wiley   +1 more source

Methylene Blue Rescue Therapy for Vasoplegic Shock After Antihypertensive Drug Overdose. [PDF]

Am J Case Rep
Aqel YHI, Karayem MMJ, Rahhal A, Hasan Koya S, Abusal AM, George S.   +5 more
europepmc   +1 more source

The Impact of Non-Adherence to Antihypertensive Drug Therapy. [PDF]

Healthcare (Basel), 2023
Gardezi SKM, Aitken WW, Jilani MH.
europepmc   +1 more source

Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort

Movement Disorders, EarlyView.
Abstract Background Previous studies on calcium channel blockers (CCBs) and Parkinson's disease (PD) risk reached conflicting conclusions. Objectives We examined the relationship between CCBs and PD in the E3N cohort of French women followed for 15 years (2004–2018), while taking into account the potential for reverse causation.
Emilie Moutard, Agnès Fournier, Émeline Courtois, Fanny Artaud, Pascale Tubert‐Bitter, Emmanuel Roze, Ismaïl Ahmed, Anne C.M. Thiébaut, Alexis Elbaz, Thi Thu Ha Nguyen   +9 more
wiley   +1 more source

Choosing the right antihypertensive drug to avoid intradialytic hypotension. [PDF]

Clin Kidney J
Zoccali C, Tripepi G, Mallamaci F, Usvyat LS, Maddux FW, Stuard S.   +5 more
europepmc   +1 more source

Melanopsin‐Mediated Post‐Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Aims To conduct a case–control study to investigate melanopsin‐mediated post‐illumination pupillary response (PIPR) in patients with Parkinson's disease (PD), video‐polysomnography‐confirmed isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), and age‐matched healthy controls (HC). Methods PIPR was measured at 6 s after
Joey W.Y. Chan, Bei Huang, Siyi Gong, Yuhua Yang, Shi Tang, Steven Wai‐ho Chau, Ngan Yin Chan, Tim Man‐ho Li, Yaping Liu, Anne Y.Y. Chan, Karen K.Y. Ma, Shirley X. Li, Joshua Tsoh, Kelvin K.L. Chong, Kathryn A. Roecklein, Vincent C.T. Mok, Yun Kwok Wing   +16 more
wiley   +1 more source

Antihypertensive Drug Target Genes and Epithelial Ovarian Cancer Risk: A Two-Sample Mendelian Randomization Study. [PDF]

Int J Womens Health
Li J, Feng Y, Shang Y.
europepmc   +1 more source

Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications

Neuroprotection, EarlyView.
Circadian dysregulation contributes to Alzheimer's disease through sleep disruption, clock‐gene dysfunction, neuroinflammation, impaired proteostasis, and metabolic imbalance. These alterations promote cognitive decline and disease progression, while circadian biomarkers and chronotherapeutic interventions offer opportunities for precision diagnosis ...
Bivek Singh, Filippo Pigazzani, Roberto Manfredini   +2 more
wiley   +1 more source